ALK
Highly Engaged Employees
Highly Engaged EmployeesManufacturing · Denmark · 1K - 5K Employees
View Company Info for Free
Overview
Headquarters
Bøge Allé 6-8, Korsholm, North Denmark, ...Phone Number
+45 45747576Website
www.alk.netRevenue
$955.8 MillionStock Symbol
ALK-BIndustry
ZI Rank: 1
Signal Type
Feb
Mar
Apr
May
Jun
Jul
ZI Rank
1
1
1
1
1
1
About ALK
ALK-Abelló is a global pharmaceutical company specializing in allergy immunotherapy treatments and diagnostics. Based in Denmark, the company develops, manufactures, and markets allergy vaccines and diagnostic products for the prevention and treatment of allergies. ALK focuses on sublingual and subcutaneous immunotherapy solutions that address respiratory allergies, including pollen, dust mites, and other allergens. The company is dedicated to improving the lives of people with allergies through innovative treatment approaches, working closely with healthcare professionals to provide evidence-based allergy care solutions worldwide.Explore more
ALK Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is ALK your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Earning: See what the market has to say on ALK recently announced quarterly report
Congratulate Masked Content for being promoted to Masked Content at ALK
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Product Launch: Get notified when ALK launches new products
Funding: Get notified immidiatlly once ALK has new funding data
Click to see if ALK had a recent Job posting/layoffs
Check if ALK has recently received funding, and reach out quickly before it becomes old news!
ALK, which may be a good buyer, showed buying intent in Masked Content Topic
Website visits: Recent activity has been detected on your website
Check out if ALK is spiking on competitors!
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 3 more new buyers
Company Profile Activity
Activity Insights
ALK is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
ALK is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about ALK.
ALK Tech Stack
A closer look at the technologies used by ALK
See more technologies
Most Recent Scoops
Hiring Plans
ALK has more open roles in Operations than it has had at any time in the past 12 months. Technologies mentioned include: SAP.
Hiring Plans
Open Position
Open Position
Open Position
Open Position
ALK News & Media
Report on transactions with ALK-Abelló A/S B shares and associated securities by managerial staff
ALK (ALKB:DC / Nasdaq Copenhagen: ALK B): In accordance with article 19 in Regulation (EU) No 596/2014 of 16 April 2014 on market abuse (the Market Abuse Regulation), ALK-Abelló A/S shall report the following transaction by managerial staff as set forth in the attached announcement.ALK appoints Jacob Glenting as head of Global R&D
ALK announces the appointment of Jacob Glenting as new Executive Vice President (EVP) and head of Global R&D, effective 1 September 2026. This position has been vacant since February 2026. Jacob Glenting is currently EVP, Corporate, Portfolio & Product Strategy (CPPS) and has been a member of the Executive Leadership Team since 2024. Prior to this, he headed up ALK’s commercial operations in international markets.Six-month interim report (Q2) 2026 (unaudited)
ALK delivers 18% organic revenue growth with operating profit (EBIT) up 19% in Q2ALK’s tree pollen and house dust mite tablets now recommended by NICE for paediatric treatment in the UK health system
ALK (ALKB:DC / Nasdaq Copenhagen: ALK B) today announced that the UK’s National Institute for Health and Care Excellence (NICE) has recommended the company’s tree pollen tablet (ITULAZAX®) and house dust mite tablet (ACARIZAX®) for children with moderate to severe allergic rhinitis whose symptoms are not controlled by symptomatic treatment. ITULAZAX® is recommended for children aged 5 to 17 with birch pollen allergy and ACARIZAX® for children aged 5 to 11 with house dust mite
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding ALK
Sign Up For FreeTo access detailed company insights
ALK-Abelló is a global pharmaceutical company specializing in allergy immunotherapy treatments and diagnostics. Based in Denmark, the company develops, manufactures, and markets allergy vaccines and diagnostic products for the prevention and treatment of allergies. ALK focuses on sublingual and subcutaneous immunotherapy solutions that address resp... Read More
